The FDA's April 2026 withdrawal of BPC-157 from Category 2 removed an explicit enforcement restriction but left the peptide without authorization for routine 503A compounding, as it is neither an approved drug nor on the official bulks list. In July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend adding BPC-157 (free base and acetate) to the 503A Bulk Drug Substances List for ulcerative colitis use, despite FDA staff briefing documents citing insufficient human safety and efficacy data and potential immunogenicity risks. This non-binding advisory step does not confer Category 1 status or enforcement discretion; any change requires formal notice-and-comment rulemaking, a process that typically spans eight to twenty-four months. No subsequent FDA action or interim Category 1 placement has been reported as of early September 2026.